Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: Evaluation of the role of G-CSF; Quality-of-life analysis and long-term follow-up

American Journal of Hematology

Volumn 66, Issue 3, 2001, Pages 178-188

  Remick, Scot C ^a   Sedransk, Nell ^a,e   Haase, Richard F ^b,c   Blanchard, Christina G ^b,c   Ramnes, Carm R ^b,c   Nazeer, Tipu ^b,c   Mastrianni, David M ^b,c   Dezube, Bruce J ^d,f  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Mount Sinai Beth Israel Department of Cardiology Beth Israel Hospital   (Israel)

Author keywords

AIDS; Non Hodgkin's lymphoma; Oral chemotherapy; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BIOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOPENIA; MALE; MENTAL DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HUMANS; LOMUSTINE; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROCARBAZINE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035113173     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200103)66:3<178::AID-AJH1042>3.0.CO;2-H     Document Type: Article

References (43)

1. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma
2. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
3. Cytokines alter production of HIV-1 from primary mononuclear phagocytes
4. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2',3-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine
5. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
6. Report of the committee on Hodgkin's disease staging classification
7. Toxicity and response criteria of the Eastern Cooperative Oncology Group
8. NCI sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
9. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group
10. Nonparametric estimation from incomplete observations
11. Measuring the quality of life of cancer patients: The functional living index - Cancer. Development and validation
12. The brief symptom inventory: An introductory report
13. Clinical and virologic effects of recombinant human granulocytemacrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
14. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
15. Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: Indications for intensive chemotherapy
16. AIDS-related malignant lymphoma: Results of prospective treatment trials
17. Lymphomas in men at high risk for acquired immune deficiency syndrome (AIDS)
18. Malignant lymphomas in patients with or at risk for AIDS in Italy
19. Aggressive non-Hodgkin's lymphoma in immunocompromised homosexual males
20. AIDS-associated non-Hodgkin's lymphoma in San Francisco
21. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York university experience
22. Retrovirus and malignant lymphoma in homosexual men
23. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial
24. AIDS-related lymphoid neoplasia: The Memorial hospital experience
25. Non-Hodgkin's lymphoma in 90 homosexual men: Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome
26. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: A highly active regimen
27. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen
28. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
29. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: A review of the Einstein, Aviano, and ECOG experience in 182 patients
30. Chemotherapy for HIV-associated non-Hodgkin lymphoma (HIV-NHL) in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity
31. Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin's lymphoma (HIV-NHL)
32. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142 (lowdose vs. standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor)
33. AIDS-related non-Hodgkin's lymphoma
34. Clinical comparison of the nitrosoureas
35. Procarbazine
36. A pilot study of the functional living index - Cancer (FLIC) scale for the assessment of quality of life for metastatic lung cancer patients
37. Quality of life assessment in lung surgery for bronchogenic carcinoma
38. Cancer patients and their physicians in the perception of psychological symptoms
39. The prevalence of psychiatric disorders among cancer patients
40. Psychosocial distress in oncology outpatients